Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer ; volume:26 ; number:1 ; day:18 ; month:1 ; year:2024 ; pages:1-13 ; date:12.2024
Breast cancer research ; 26, Heft 1 (18.1.2024), 1-13, 12.2024
- Urheber
-
Fisher, Timothy B.
Saini, Geetanjali
Rekha, T. S.
Krishnamurthy, Jayashree
Bhattarai, Shristi
Callagy, Grace
Webber, Mark
Janssen, Emiel A. M.
Kong, Jun
Aneja, Ritu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13058-023-01752-y
- URN
-
urn:nbn:de:101:1-2024033110325005084235
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fisher, Timothy B.
- Saini, Geetanjali
- Rekha, T. S.
- Krishnamurthy, Jayashree
- Bhattarai, Shristi
- Callagy, Grace
- Webber, Mark
- Janssen, Emiel A. M.
- Kong, Jun
- Aneja, Ritu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
CD44v9 as a poor prognostic factor of triple-negative breast cancer treated with neoadjuvant chemotherapy
A Brief Review of Treatment Options for Neoadjuvant Chemotherapy in Patients with Triple-negative Breast Cancer
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancer
Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
Patient-reported outcomes from a randomized trial of neoadjuvant atezolizumab-chemotherapy in early triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer